PROJECT 1 This project will develop and evaluate a comprehensive and integrated suite of analytical, computational, and bioassay based approaches for assessing overall reductions in toxicity resulting from bioremediation of Superfund (SF) sites. These tools will then be applied to optimize biodegradation of two contaminant mixtures, triazine herbicides and polycyclic aromatic hydrocarbons representative of environmental exposures faced by our community partners the Yurok Tribe, through systematic investigation of carbon sources, electron acceptors, and reactor detention times. Although both of these contaminant mixtures are known to biodegrade, transformation products (TPs) accumulate and are widely found in groundwater (triazines) and/or have increased toxicity compared to parent compounds (PAHs). Bioreactor performance will be characterized by measuring shifts in microbial community composition, bioassay activity, and both target and nontarget chemical concentrations measured with GC and LC high resolution mass spectrometry (HRMS). This combination of measurements will provide unique insights into interactions among contaminant transformations, microbial populations and overall reductions in human and ecosystem risks. Novel enzyme engineering approaches will be used to identify rate limiting steps in triazine mineralization and to isolate or design improved enzymes to carry out these steps. Microorganisms with improved ability to degrade triazines will be prepared and tested in the bioreactors to assess ability to remove target compounds and to reduce overall bioactivity compared to standard enrichment approaches. Our central hypothesis is that chemical hazard reduction during SF site remediation can be best characterized through broad consideration of both contaminant destruction and byproduct formation. We further hypothesize that a minimum suite of high- throughput assays can be defined to effectively capture the overall risk reduction during remediation and that this suite of assays can guide optimization of bioreactor design and operation. This project will support a paradigm shift in the SRP away from reducing concentrations of specific constituents and toward the overall reduction of deleterious biological effects. The project is strongly integrated with the overall program, drawing on HRMS, metabolomics, and statistical expertise in the Analytical Core, the full range of bioassays available in the Bioanalytical Core, immunoassays from Project 3 especially for triazines and TPs, as well as integrative bioassays for ER and oxidative stress being developed by Projects 4 and 5. The bioassay suite developed here will be used to analyze environmental samples collected through the Community Engagement Core and the overall workflow will be transferred to a broader user community with the assistance of the Research Translation Core.

Public Health Relevance

PROJECT 1 Bioremediation is often limited for superfund site remediation by slow transformation rates and/or buildup of transformation products, possibly having higher toxicity than the parent compounds. This project will demonstrate significant improvements in bioremediation via a multi-prong effort involving non-target chemical analysis, a comprehensive suite of bioassays and enzyme engineering. It will thus lead to reductions in human exposure to bioactive compounds and to more rapid and effective site cleanups, making it of direct interest to Superfund Research Program stakeholders, especially communities like the Yurok Tribe that face unknown contamination scenarios.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Hazardous Substances Basic Research Grants Program (NIEHS) (P42)
Project #
2P42ES004699-29A1
Application #
9259774
Study Section
Special Emphasis Panel (ZES1)
Project Start
Project End
Budget Start
2017-07-01
Budget End
2018-03-31
Support Year
29
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Taha, Ameer Y; Hennebelle, Marie; Yang, Jun et al. (2018) Regulation of rat plasma and cerebral cortex oxylipin concentrations with increasing levels of dietary linoleic acid. Prostaglandins Leukot Essent Fatty Acids 138:71-80
Hill 3rd, Thomas; Rice, Robert H (2018) DUOX expression in human keratinocytes and bronchial epithelial cells: Influence of vanadate. Toxicol In Vitro 46:257-264
Kodani, Sean D; Wan, Debin; Wagner, Karen M et al. (2018) Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors. ACS Omega 3:14076-14086
Ren, Qian; Ma, Min; Yang, Jun et al. (2018) Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease. Proc Natl Acad Sci U S A 115:E5815-E5823
Pecic, Stevan; Zeki, Amir A; Xu, Xiaoming et al. (2018) Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability. Prostaglandins Other Lipid Mediat 136:90-95
Yamanashi, Haruto; Boeglin, William E; Morisseau, Christophe et al. (2018) Catalytic activities of mammalian epoxide hydrolases with cis and trans fatty acid epoxides relevant to skin barrier function. J Lipid Res 59:684-695
Wang, Fuli; Zhang, Hongyong; Ma, Ai-Hong et al. (2018) COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Mol Cancer Ther 17:474-483
Napimoga, M H; Rocha, E P; Trindade-da-Silva, C A et al. (2018) Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption. J Periodontal Res 53:743-749
Blöcher, René; Wagner, Karen M; Gopireddy, Raghavender R et al. (2018) Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain. J Med Chem 61:3541-3550
Hao, Lei; Kearns, Jamie; Scott, Sheyenne et al. (2018) Indomethacin Enhances Brown Fat Activity. J Pharmacol Exp Ther 365:467-475

Showing the most recent 10 out of 1149 publications